Europe's Premier End-to-End Forum for Targeted Radiopharmaceutical Development
With radioligand therapies rapidly expanding into new tumour types, novel targets and emerging therapeutic isotopes, the race to develop and commercialise next-generation radiopharmaceuticals is accelerating across Europe.
From securing reliable isotope access and scaling GMP manufacturing to generating robust clinical evidence, optimising dosimetry and preparing for commercial launch, the need for integrated scientific and operational strategies has never been greater.
Returning to London, the 8th Targeted Radiopharmaceuticals Summit Europe unites Europe's leading biopharma innovators, regulators, clinicians and solution providers for the industry's most comprehensive end-to-end meeting dedicated exclusively to radiopharmaceutical development.
Covering discovery, preclinical development, clinical translation, CMC, manufacturing, regulatory strategy and commercial readiness, the 2026 programme is designed to equip teams with practical insights, strategic connections and real-world case studies needed to accelerate the development and delivery of next-generation radiopharmaceutical therapies.
Join Europe's dedicated radiopharmaceutical community to benchmark your strategy, forge new partnerships and gain the expertise required to overcome the scientific, operational and regulatory hurdles shaping the future of the field. Connect with the stakeholders driving innovation across the value chain and help accelerate the delivery of transformative treatments to patients.
Key Focus Areas Include:
Accelerating Discovery & Preclinical Innovation
Discover how leading developers are identifying novel targets, engineering next-generation radiopharmaceutical platforms and generating the translational evidence needed to confidently progress programmes from discovery into first-in-human studies.
Advancing Clinical Translation & Earlier-Line Therapies
Learn from late-stage clinical programmes and leading treatment centres as they share strategies for optimising trial design, patient selection, dosimetry and expanding radioligand therapies into earlier lines of care and new indications.
Building Resilient CMC, Manufacturing & Isotope Supply Strategies
Explore the latest approaches to securing isotope supply, scaling GMP manufacturing, implementing automation and strengthening quality systems to support reliable clinical development and future commercial demand.
Navigating Europe's Evolving Regulatory Landscape
Hear directly from MHRA, Swissmedic, the IAEA and the Office for Nuclear Regulation on the latest regulatory expectations, licensing considerations and strategies for accelerating clinical and commercial radiopharmaceutical development across Europe.
Where Europe's Radiopharmaceutical Community Connects to Accelerate Progress
Targeted radiopharmaceuticals have entered a new era. Clinical success is accelerating investment, pharma pipelines are rapidly expanding, and next-generation alpha emitters, novel targets and precision radioligand therapies are redefining the future of oncology. As the field evolves, the industry's greatest challenge is translating innovation into scalable, clinically successful and commercially viable therapies.
From discovering differentiated targets and generating robust clinical evidence to securing isotope supply, scaling GMP manufacturing and navigating increasingly complex regulatory pathways, developers must now overcome a new generation of scientific, operational and commercial bottlenecks.
As Europe's definitive end-to-end targeted radiopharmaceuticals forum, the 8th Targeted Radiopharmaceuticals Summit Europe returns to London to unite the organisations shaping the future of radioligand therapy. Bringing together leaders across discovery, clinical development, CMC, manufacturing, isotope supply, regulatory affairs, clinical practice and investment, the 2026 programme has been designed to provide practical strategies that accelerate transformative radiopharmaceuticals from discovery to patients.
Europe's Most Comprehensive End-to-End Forum Dedicated
to Targeted Radiopharmaceutical Development
- 50+ World-Class Speakers from Across the TRP Ecosystem
- 20+ Hours of Curated Networking, Including Meet & Match Partnering
- 15+ Exclusive Clinical Readouts & Real-World Case Studies
- Brand-New Interactive Workshops & Seminars
- Europe's Strongest Regulatory Faculty (MHRA, Swissmedic, IAEA & ONR)
- The Great Isotope Debate
Explore the Agenda
Discover the scientific, clinical and commercial strategies that will become your blueprint for accelerating targeted radiopharmaceuticals from discovery to patients.
Partner With Us
Showcase your technologies and services to 200+ senior decision-makers actively seeking CROs, CDMOs, isotope suppliers, radiopharmacies, dosimetry providers and specialist partners to advance the next generation of radiopharmaceuticals.
Join Europe's TRP Leaders:
Be part of Europe's most comprehensive targeted radiopharmaceuticals forum, uniting pharma, biotech, regulators, clinical centres, investors and solution providers to shape the future of radioligand therapy.